Zobrazeno 1 - 10
of 25
pro vyhledávání: '"KOICHI OHATA"'
Autor:
Hironori Fujii, Akitaka Makiyama, Kayoko Nishimura, Hirotoshi Iihara, Chiemi Hirose, Koichi Ohata, Yunami Yamada, Daichi Watanabe, Itaru Yasufuku, Naoki Okumura, Yoshihiro Tanaka, Takao Takahashi, Ryo Kobayashi, Nobuhisa Matsuhashi, Akio Suzuki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Background Anamorelin is expected to improve cancer cachexia by increasing lean body mass (LBM) due to increased appetite and protein synthesis. However, the effect of anamorelin on cancer cachexia in real-world practice is unclear. The purp
Externí odkaz:
https://doaj.org/article/ee8816608d5f438b928ba67da044ed10
Autor:
Daichi Watanabe, Hironori Fujii, Koichi Ohata, Hirotoshi Iihara, Akitaka Makiyama, Ryo Kobayashi, Chiemi Hirose, Shiori Hishida, Serika Matsuoka, Jesse Yu Tajima, Shigeru Kiyama, Takao Takahashi, Akio Suzuki, Nobuhisa Matsuhashi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102). Because some of these studies failed to address immortality time bias, howev
Externí odkaz:
https://doaj.org/article/cb8ce677d92a4090b254e842a7afaacd
Autor:
Hironori Fujii, Yukino Ueda, Chiemi Hirose, Koichi Ohata, Kumiko Sekiya, Mika Kitahora, Shiori Sadaka, Senri Yamamoto, Daichi Watanabe, Hiroko Kato-Hayashi, Hirotoshi Iihara, Ryo Kobayashi, Miho Kaburaki, Nobuhisa Matsuhashi, Takao Takahashi, Akitaka Makiyama, Kazuhiro Yoshida, Hideki Hayashi, Akio Suzuki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Background The effect of pharmaceutical intervention to treat adverse events on quality of life (QOL) in outpatients receiving cancer chemotherapy is unclear. We investigated whether pharmaceutical intervention provided by pharmacists in col
Externí odkaz:
https://doaj.org/article/3e27ad5d37c74e7f8a5a46f83069ed5b
Autor:
Hironori Fujii, Maaya Koda, Shiori Sadaka, Koichi Ohata, Hiroko Kato-Hayashi, Hirotoshi Iihara, Ryo Kobayashi, Takuma Ishihara, Shinya Uemura, Takuji Iwashita, Hideki Hayashi, Tadashi Sugiyama, Masahito Shimizu, Akio Suzuki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Background Cancer chemotherapy usually improves clinical outcomes in patients with advanced pancreatic cancer (APC), but can also cause moderate-to-severe adverse events (AEs). We investigated the relationship between moderate-to-severe AEs
Externí odkaz:
https://doaj.org/article/20cd3bc9f2cc45b9849e89ea00afb9ea
Autor:
Shiori Sadaka, Takuji Iwashita, Hironori Fujii, Hiroko Kato-Hayashi, Koichi Ohata, Shinya Uemura, Masahito Shimizu, Akio Suzuki
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 19, p 5895 (2022)
Modified FOLFIRINOX (mFFX) and Gemcitabine plus nab-paclitaxel (GnP) are effective first-line chemotherapies for unresectable advanced pancreatic cancer (APC); however, both lead to peripheral neuropathy (PN). Aims: To evaluate the impact of first-li
Externí odkaz:
https://doaj.org/article/160e270cafa94150987cfadf19cd762b
Autor:
Yunami Yamada, Hironori Fujii, Daichi Watanabe, Hiroko Kato-Hayashi, Koichi Ohata, Ryo Kobayashi, Takuma Ishihara, Shinya Uemura, Takuji Iwashita, Masahito Shimizu, Akio Suzuki
Publikováno v:
Cancers, Vol 10, Iss 11, p 454 (2018)
While modified FOLFIRINOX therapy is effective for treating advanced pancreatic cancer, it frequently causes severe neutropenia. The present study investigated the effect of severe neutropenia on clinical outcomes in advanced pancreatic cancer patien
Externí odkaz:
https://doaj.org/article/7cac3b6314ca4d109f9f81cf8d276524
Autor:
SERIKA MATSUOKA, HIRONORI FUJII, HIROTOSHI IIHARA, KOICHI OHATA, CHIEMI HIROSE, DAICHI WATANABE, SHIORI SADAKA, SHIGERU KIYAMA, AKITAKA MAKIYAMA, TAKAO TAKAHASHI, RYO KOBAYASHI, NOBUHISA MATSUHASHI, AKIO SUZUKI
Publikováno v:
Anticancer Research. 43:2351-2357
Autor:
Shiori Sadaka, Hideki Hayashi, Hirotoshi Iihara, Maaya Koda, Shinya Uemura, Hiroko Kato-Hayashi, Akio Suzuki, Hironori Fujii, Ryo Kobayashi, Tadashi Sugiyama, Takuma Ishihara, Masahito Shimizu, Takuji Iwashita, Koichi Ohata
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 7, Iss 1, Pp 1-7 (2021)
Journal of Pharmaceutical Health Care and Sciences
Journal of Pharmaceutical Health Care and Sciences
Background Cancer chemotherapy usually improves clinical outcomes in patients with advanced pancreatic cancer (APC), but can also cause moderate-to-severe adverse events (AEs). We investigated the relationship between moderate-to-severe AEs and quali
Autor:
HIRONORI FUJII, SHIORI SADAKA, KANAE AJISAWA, NAOKI OKUMURA, AKITAKA MAKIYAMA, HIROTOSHI IIHARA, ITARU YASUFUKU, KOICHI OHATA, RYO KOBAYASHI, YOSHIHIRO TANAKA, HIDEKI HAYASHI, AKIO SUZUKI
Publikováno v:
Anticancer research. 42(9)
Although peripheral neuropathy (PN) is a common adverse event in patients treated with oxaliplatin as first-line chemotherapy (1st-OX) for advanced gastric cancer, the effect of PN on the efficacy of paclitaxel at second-line chemotherapy (2nd-PTX) r
Autor:
Hisashi Tsurumi, Senji Kasahara, Yasuyuki Nagata, Hiroko Kato-Hayashi, Yoshinori Itoh, Michio Sawada, Masahito Shimizu, Koichi Ohata, Akio Suzuki, Hideki Hayashi, Takaaki Ono, Ryo Kobayashi, Junichi Kitagawa
Publikováno v:
International Journal of Cancer. 148(6):1462-1469
Oral mucositis is a common and distressing complication in patients receiving high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT). We reported previously in a single-center retrospective analysis that zinc-L-carnosine (p